Pulsenmore (NASDAQ: PLSM) reported a quarterly loss of $(1.83) per share. The company recorded sales of $2.042 million for the period.

The results highlight the company's ongoing profitability challenges amid modest revenue generation. With earnings per share in negative territory, the firm faces pressure to improve operational efficiency or scale revenue to offset costs.

Financial Performance

The company’s top-line performance stood at $2.042 million. This revenue figure provides context for the per-share loss, indicating that current sales volumes are insufficient to cover operational and other expenses on a per-share basis.

What the Numbers Show

The divergence between the absolute sales figure and the per-share loss suggests high fixed costs or significant non-operating expenses relative to revenue. Without data on share count or gross margins, the exact driver remains opaque, but the magnitude of the EPS loss relative to the small revenue base indicates a steep path to breakeven.

Pulsenmore Ltd. has been selected to lead a $1 million AI development project within Israel's Healthcare AI Regulatory Sandbox Program, established by the Israel Innovation Authority (IIA) and the Ministry of Health. This initiative will enable the company to develop and clinically validate AI applications designed to improve clinical workflow efficiency and enhance the scalability of its home ultrasound platform. The program aims to accelerate the adoption of breakthrough healthcare AI technologies through a unique regulatory framework that facilitates collaboration between companies, regulators, and the healthcare system.

The project leverages data from more than 250,000 home ultrasound scans performed using the Pulsenmore platform, creating the world's largest real-world datasets of prenatal home ultrasound scans. This dataset provides a foundation for developing AI tools that automatically identify key ultrasound parameters. By streamlining the review process, the company expects to enable clinicians to focus on clinically relevant information, reduce review time, and deliver results to patients more quickly, addressing the global shortage of skilled healthcare professionals.

Pulsenmore will collaborate with Beilinson Hospital, part of the Clalit Health Services network, on the development and clinical validation of its AI applications. Dr. Elazar Sonnenschein, Founder and CEO of Pulsenmore, stated that the program represents the next stage in the platform's evolution, aiming to equip physicians with tools to work more efficiently and care for more patients without compromising quality.

Strategic Deployment

Pulsenmore's home ultrasound platform allows pregnant women to perform physician-prescribed scans from home using a device connected to a smartphone. Examinations are securely transmitted to a physician for interpretation. The technology is currently deployed by leading healthcare organizations, including Clalit Health Services, Israel's largest Health Maintenance Organization (HMO), and other clinical partners worldwide.

Program Objectives

The Healthcare AI Regulatory Sandbox Program focuses on several critical goals:

• Accelerate the adoption of breakthrough healthcare AI technologies.
• Enable companies to develop and evaluate innovative solutions alongside regulators.
• Clinically validate applications to ensure safety and efficacy.
• Establish efficient pathways for integrating AI into healthcare systems globally.